Lonza's ResistAid Increases Antibody Response

BASEL,SwitzerlandAccording to Lonza, new research demonstrates the ability of ResistAida proprietary ingredient made from larch trees and an arabinogalactan-based immune support ingredientto increase the antibody response in healthy adults after exposure to the etanus vaccine.

The study found the efficacy of ResistAid-at a significantly lower dosage of 1.5 g/d was as effective as the previous dosage of 4.5g/d. The findings were recently published in the October issue of Journal of the American College of Nutrition.
 
This study further validates the capability of ResistAid to influence an expected and beneficial response from the immune system, while simultaneously confirming its ability to do so at a low dosage," said Michael DeGennaro, NAFTA vice president of sales human nutrition, Lonza Inc. In combination with its positive effects on both the innate and adaptive arms of the immune system, ResistAid is highly formulation-friendly. It can be easily incorporated into dietary supplements and functional foods in standalone form, or combined with other products to increase functionality."
 
Vaccines trigger in vivo immune responses, which are indicators of immune function. The vaccine model is widely used to evaluate the impact a nutrient has on normal immune function and provides high-quality information on the protective effect a nutrient has on in vivo immune responsiveness.
 
In the double blind study, subjects included 75 healthy adults between the ages of 18 to 61 years old, who were randomized to receive either 1.5 g/d or 4.5 g/d of ResistAid or placebo for 60 days. At day 30, subjects were administered both tetanus and influenza vaccines. Serum antigenic response were measured at 45 and 60 days and compared to baseline antibody levels. As expected, all three groups demonstrated a rise in tetanus IgG levels 15 and 30 days following the vaccine. There was a significant difference in the rise in tetanus IgG levels at day 60 in the 1.5 g/d group compared to placebo. Neither group demonstrated any significant elevations in IgM or IgG antibodies compared to placebo following the influenza vaccine.  
 
ResistAid is manufactured according to hazard analysis critical control points (HACCP). It is good manufacturing practices (GMP)-audited by the American Institute of Baking, is kosher certified by the United Mehadrin, genetically modified organisms (GMO)-free and self-affirmed generally recognized as safe (GRAS).